Johnson & Johnson (JNJ) News
Filter JNJ News Items
JNJ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JNJ News Highlights
- 500 - Internal server error
- Over the past 29 days, the trend for JNJ's stories per day has been choppy and unclear. It has oscillated between 1 and 20.
- MRNA, DELL and VC are the most mentioned tickers in articles about JNJ.
Latest JNJ News From Around the Web
Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
Brazil looks at extending expiry date of J&J COVID vaccinesBrazil's health regulator Anvisa met with representatives of Johnson & Johnson subsidiary Janssen on Friday to discuss extending the expiry date of a batch of 3 million doses of its COVID vaccine bought by the South American nation. The batch of vaccines expires on June 27. |
Johnson & Johnson Can’t Use 60 Million Covid Doses Because of Possible Contamination, FDA RulesThe government agency based the decision on quality-control problems at the Emergent BioSolutions plant where the vaccine was made. |
Seattle becomes first major U.S.city with 70% fully vaccinatedSeattle Mayor Jenny Durkan joined Yahoo Finance to break down how her city has been so sucsseful in distrubting vaccines. |
COVID SCIENCE-Vaccines effective vs variants despite diminished antibodies; kids may be as contagious as adultsThe following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. The one-dose Johnson & Johnson COVID-19 vaccine and the two-dose vaccine from Pfizer and BioNTech appear to protect against worrisome coronavirus variants despite diminished levels of antibodies that can neutralize the newer versions of the virus, two studies in the journal Nature suggest. |
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYTThe FDA has asked Johnson & Johnson (NYSE: JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the troubled Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore plant, the New York Times reported, citing people familiar with the matter. A further 10 million JNJ doses would be allowed to be distributed with a warning that there was no guarantee that Emergent BioSolutions had followed proper practices. The FDA said it had agreed that two batches of the vaccine were authorized for |
Dow Slips, Small Caps Lead Upside, Nasdaq Holds Gain; These Biotech Stocks Make Notable MovesThe Dow Jones traded slightly lower in today's market after paring an earlier gain. Over the past hour, the indexes traded near their lows. |
New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effectsThe number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. |
CDC plans 'emergency meeting' over COVID-19 vaccine side effectsYahoo Finance's Anjalee Khemlani reports on the CDC's plans for an 'emergency meeting' over COVID-19 vaccine side effects. |
Dow Jones Slips As These 2 Key Stocks Weigh; Nasdaq Aims For Big Weekly GainStocks were mixed midday Friday, as the Nasdaq edged higher but Caterpillar and Johnson & Johnson pressured the Dow Jones Industrial Average. |
UPDATE 6-U.S. FDA asks J&J to discard millions of COVID-19 vaccine dosesThe U.S. Food & Drug Administration on Friday said Johnson & Johnson must throw away millions of doses of its COVID-19 vaccine that were manufactured at a problem-plagued Baltimore factory but also cleared millions for use. Without disclosing or confirming the number of vaccine doses, the FDA said in a news release that it had authorized two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated. The agency said it was not yet ready to authorize Emergent BioSolutions Inc's plant for manufacturing the J&J vaccine. |